Editorial 213

ESC guidelines on diabetes, ECHO-TR trial, and more

In this issue, we have a very good review of the new European Society of Cardiology Guidelines on diabetes; prediabetes, and cardiovascular diseases written by Prof. Fras, from Slovenia. He focuses on whether the new guidelines are a truly strong base for a major paradigm shift in clinical practice.

Another review comes to us from Romania. Grigoras et al. provide an update on perivascular adipose tissue (PVAT) in cardiovascular diseases. They summarize the current knowledge and discuss the role of PVAT as a major contributing factor in the pathogenesis of ischemic coronary disease, hypertension, obesity, and diabetes mellitus.

Li Zhao, from China, reports on the alleviation of oxidative stress and mitochondrial dysfunction with trimetazidine and coenzyme Q10 in cisplatin-induced cardiotoxicity in isolated rat cardiomyocytes.

Tunçez et al., from Turkey, compare the pleiotrophic effects of atorvastatin and rosuvastatin on the serum levels of endocan, chemerin, and galectin-3 in patients with acute myocardial infarction.

Adding a new factor to the etiopathogenesis of coronary artery ectasia (CAE), Özkan et al., from Turkey, analyze the association between low serum adropin level and isolated CAE.

Ning et al., from China, examine big endothelin-1 as a clinical marker for ventricular tachyarrhythmia in post-infarction left ventricular aneurysm.

In a special trial that included 31centers from across Turkey, Şafak et al. present "Normal echocardiographic measurements in a Turkish population: The Healthy Heart ECHO-TR Trial." This study will be helpful to echocardiographers in their clinical practice.

In addition, we have interesting case reports, letters, and e-pages.

I hope this issue will be of interest to our readers.

Prof. Dr. Çetin Erol Editor-in-Chief Ankara-*Turkey*

